Fatty acyl-chain remodeling by LPCAT3 enriches arachidonate in phospholipid membranes and regulates triglyceride transport

  1. Tomomi Hashidate-Yoshida
  2. Takeshi Harayama
  3. Daisuke Hishikawa
  4. Ryo Morimoto
  5. Fumie Hamano
  6. Suzumi M Tokuoka
  7. Miki Eto
  8. Miwa Tamura-Nakano
  9. Rieko Yanobu-Takanashi
  10. Yoshiko Mukumoto
  11. Hiroshi Kiyonari
  12. Tadashi Okamura
  13. Yoshihiro Kita
  14. Hideo Shindou
  15. Takao Shimizu  Is a corresponding author
  1. National Center for Global Health and Medicine, Japan
  2. National Center for Global Health and Medicine, Switzerland
  3. The University of Tokyo, Japan
  4. RIKEN Center for Developmental Biology, Japan

Abstract

Polyunsaturated fatty acids (PUFAs) in phospholipids affect the physical properties of membranes, but it is unclear which biological processes are influenced by their regulation. For example, the functions of membrane arachidonate that are independent of a precursor role for eicosanoid synthesis remain largely unknown. Here, we show that the lack of lysophosphatidylcholine acyltransferase 3 (LPCAT3) leads to drastic reductions in membrane arachidonate levels, and that LPCAT3-deficient mice are neonatally lethal due to an extensive triacylglycerol (TG) accumulation and dysfunction in enterocytes. We found that high levels of PUFAs in membranes enable TGs to locally cluster in high density, and that this clustering promotes efficient TG transfer. We propose a model of local arachidonate enrichment by LPCAT3 to generate a distinct pool of TG in membranes, which is required for normal directionality of TG transfer and lipoprotein assembly in the liver and enterocytes.

Article and author information

Author details

  1. Tomomi Hashidate-Yoshida

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  2. Takeshi Harayama

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Switzerland
    Competing interests
    No competing interests declared.
  3. Daisuke Hishikawa

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  4. Ryo Morimoto

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    Ryo Morimoto, Department of Lipidomics, the University of Tokyo is financially supported by Shimadzu Co., and ONO Phamraceutical Col. Ltd..
  5. Fumie Hamano

    Department of Lipidomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Competing interests
    Fumie Hamano, Department of Lipidomics, the University of Tokyo is financially supported by Shimadzu Co., and ONO Phamraceutical Col. Ltd..
  6. Suzumi M Tokuoka

    Department of Lipidomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Competing interests
    Suzumi M Tokuoka, Department of Lipidomics, the University of Tokyo is financially supported by Shimadzu Co., and ONO Phamraceutical Col. Ltd..
  7. Miki Eto

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    Miki Eto, Department of Lipidomics, the University of Tokyo is financially supported by Shimadzu Co., and ONO Phamraceutical Col. Ltd..
  8. Miwa Tamura-Nakano

    Communal Laboratory, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  9. Rieko Yanobu-Takanashi

    Department of Laboratory Animal Medicine, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  10. Yoshiko Mukumoto

    Laboratory for Animal Resources and Genetic Engineering, RIKEN Center for Developmental Biology, Kobe, Japan
    Competing interests
    No competing interests declared.
  11. Hiroshi Kiyonari

    Laboratory for Animal Resources and Genetic Engineering, RIKEN Center for Developmental Biology, Kobe, Japan
    Competing interests
    No competing interests declared.
  12. Tadashi Okamura

    Department of Laboratory Animal Medicine, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  13. Yoshihiro Kita

    Department of Lipidomics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Competing interests
    Yoshihiro Kita, Department of Lipidomics, the University of Tokyo is financially supported by Shimadzu Co., and ONO Phamraceutical Col. Ltd..
  14. Hideo Shindou

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan
    Competing interests
    No competing interests declared.
  15. Takao Shimizu

    Department of Lipid Signaling, National Center for Global Health and Medicine, Tokyo, Japan
    For correspondence
    tshimizu@ri.ncgm.go.jp
    Competing interests
    Takao Shimizu, Department of Lipidomics, the University of Tokyo is financially supported by Shimadzu Co., and ONO Phamraceutical Col. Ltd..

Ethics

Animal experimentation: All animal experiments were approved by and performed in accordance with the guidelines of the Animal Research Committee of National Center for Global Health and Medicine (12053, 13009, 14045), and the animal experimentation committee of the University of Tokyo (H09-144, P08-042).

Copyright

© 2015, Hashidate-Yoshida et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 5,145
    views
  • 1,376
    downloads
  • 197
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Tomomi Hashidate-Yoshida
  2. Takeshi Harayama
  3. Daisuke Hishikawa
  4. Ryo Morimoto
  5. Fumie Hamano
  6. Suzumi M Tokuoka
  7. Miki Eto
  8. Miwa Tamura-Nakano
  9. Rieko Yanobu-Takanashi
  10. Yoshiko Mukumoto
  11. Hiroshi Kiyonari
  12. Tadashi Okamura
  13. Yoshihiro Kita
  14. Hideo Shindou
  15. Takao Shimizu
(2015)
Fatty acyl-chain remodeling by LPCAT3 enriches arachidonate in phospholipid membranes and regulates triglyceride transport
eLife 4:e06328.
https://doi.org/10.7554/eLife.06328

Share this article

https://doi.org/10.7554/eLife.06328

Further reading

    1. Biochemistry and Chemical Biology
    2. Computational and Systems Biology
    A Sofia F Oliveira, Fiona L Kearns ... Adrian J Mulholland
    Short Report

    The spike protein is essential to the SARS-CoV-2 virus life cycle, facilitating virus entry and mediating viral-host membrane fusion. The spike contains a fatty acid (FA) binding site between every two neighbouring receptor-binding domains. This site is coupled to key regions in the protein, but the impact of glycans on these allosteric effects has not been investigated. Using dynamical nonequilibrium molecular dynamics (D-NEMD) simulations, we explore the allosteric effects of the FA site in the fully glycosylated spike of the SARS-CoV-2 ancestral variant. Our results identify the allosteric networks connecting the FA site to functionally important regions in the protein, including the receptor-binding motif, an antigenic supersite in the N-terminal domain, the fusion peptide region, and another allosteric site known to bind heme and biliverdin. The networks identified here highlight the complexity of the allosteric modulation in this protein and reveal a striking and unexpected link between different allosteric sites. Comparison of the FA site connections from D-NEMD in the glycosylated and non-glycosylated spike revealed that glycans do not qualitatively change the internal allosteric pathways but can facilitate the transmission of the structural changes within and between subunits.

    1. Biochemistry and Chemical Biology
    2. Genetics and Genomics
    Conor J Howard, Nathan S Abell ... Nathan B Lubock
    Research Article

    Deep Mutational Scanning (DMS) is an emerging method to systematically test the functional consequences of thousands of sequence changes to a protein target in a single experiment. Because of its utility in interpreting both human variant effects and protein structure-function relationships, it holds substantial promise to improve drug discovery and clinical development. However, applications in this domain require improved experimental and analytical methods. To address this need, we report novel DMS methods to precisely and quantitatively interrogate disease-relevant mechanisms, protein-ligand interactions, and assess predicted response to drug treatment. Using these methods, we performed a DMS of the melanocortin-4 receptor (MC4R), a G-protein-coupled receptor (GPCR) implicated in obesity and an active target of drug development efforts. We assessed the effects of >6600 single amino acid substitutions on MC4R’s function across 18 distinct experimental conditions, resulting in >20 million unique measurements. From this, we identified variants that have unique effects on MC4R-mediated Gαs- and Gαq-signaling pathways, which could be used to design drugs that selectively bias MC4R’s activity. We also identified pathogenic variants that are likely amenable to a corrector therapy. Finally, we functionally characterized structural relationships that distinguish the binding of peptide versus small molecule ligands, which could guide compound optimization. Collectively, these results demonstrate that DMS is a powerful method to empower drug discovery and development.